Czech Innovation Against Alzheimer’s: H2 Global Group Enters a Key Growth Phase

Czech Innovation Against Alzheimer’s: H2 Global Group Enters a Key Growth Phase

by | Oct 2, 2025 | Alzheimer, Health, Neurology, Spa, Sport, Stomatology, Veterina

H2 Global Group, together with its subsidiary H2 Medical Technologies, has entered a decisive growth stage following strong recognition at LSI Europe 2025 in London. The group presented its breakthrough approach to preventing and treating neurodegenerative diseases, including Alzheimer’s, confirming its position among global leaders in the MedTech and HealthTech sectors.

At the core of this innovation is a prototype medical device for controlled hydrogen therapy, developed by H2 Medical Technologies. The device is designed for patients with mild cognitive impairment, a condition that often precedes Alzheimer’s. Non-invasive and suitable for both clinical and home use, it is based on a patented method pioneered by a Japanese team led by Professor Shigeo Ohta, co-owner of H2 Global Group. Research indicates that molecular hydrogen can protect brain cells, slow inflammation, and support neuronal metabolism and connectivity.

“Hydrogen is the smallest molecule in the universe, yet it can protect our most valuable assets – memory and independence,” explains Prof. Ohta.

Group founder David Maršálek, who has been developing hydrogen technologies since 2011, adds: “Our mission is to launch the world’s first hydrogen-based medical device for Alzheimer’s prevention and therapy support. With strong scientific evidence, patent protection, and an experienced team, we are positioned to succeed.”

Between 2021 and 2025, H2 Global Group raised over $18M in Seed funding, built a network of 20,000 end-customers and 50+ B2B partners, and exceeded revenues of circa $7.4M. Current transactions value the group at circa $77M.

Now entering Series A, the group plans to raise $25–30 million to fund global expansion into Europe, the U.S., the Middle East, and Africa, complete clinical trials, and secure EU and FDA registrations. Revenue projections forecast growth to nearly $48M by 2029.

The portfolio extends beyond the medical device. H2 Medical Technologies supplies hydrogen generators and therapeutic systems to spas, sports clubs, physiotherapy practices or dental clinics. Its solutions are also approved for veterinary use. In parallel, H2 Pharm develops consumer products such as H2 Premium Water®, H2 Brain®, H2 Forte®, and H2 Dent Care®, which are commercially successful and distributed via e-commerce and a B2B network.

“Such opportunities are rare,” concludes Maršálek. “When future textbooks are written, our investors will say: I was there. Hydrogen is not only energy source but a molecule of lifeconnecting the world. Invest in Hydrogen!”

Source: ap.news.com

Czech MedTech Startup H2 Medical Technologies Unveils World’s First Patented Hydrogen-Based Therapy with the Potential to Target Alzheimer’s Disease

Czech MedTech Startup H2 Medical Technologies Unveils World’s First Patented Hydrogen-Based Therapy with the Potential to Target Alzheimer’s Disease

by | Oct 2, 2025 | Alzheimer, Health, Neurology, Spa, Sport, Stomatology, Veterina

H2 Medical Technologies, part of the H2 Global Group, has developed the world’s first functional hydrogen-based therapy medical device prototype for clinical trials — aimed at both preventing and treating Alzheimer’s disease.

Today, more than 6.5 million Americans and 50 million people worldwide are living with Alzheimer’s and other forms of dementia. According to the World Health Organization, this number could triple by 2050, placing an immense burden on families and healthcare systems. Despite decades of research, no effective solution has been found — until now.

“This is not another experiment — it is the first technology in the world with the potential to prevent Alzheimer’s disease before it even starts, while supporting those already affected,” says David Marsalek, founder and CEO of H2 Global Group. The company believes its effectiveness will be further confirmed in an upcoming new clinical trial. “Our mission is clear: to turn decades of research into real hope for millions of families around the world. We are part of a strong vision of a society where hydrogen is the molecule of life that connects the world.”

From the Lab to the Global Stage

H2 Global Group will present this breakthrough at LSI Europe 2025 in London, one of the world’s most prestigious MedTech and HealthTech conferences. The project builds on 30+ years of research and patents developed with Professor Shigeo Ohta, a global leader in molecular hydrogen science and co-founder of H2 Global Group.

More Than Medicine: A New Era of Brain Health

While the immediate focus is Alzheimer’s, potential applications extend to neurological disorders, brain regeneration, and healthy aging.

Alongside its medical device, H2 Global Group has launched consumer products such as H2 Premium Water® and H2 Brain®, a world-first two-phase dietary supplement that stimulates molecular hydrogen production through the gut microbiome. The company is also the only certified global manufacturer authorized to use hydrogen-based medical devices in veterinary medicine.

Today, its hydrogen-based solutions are already being adopted by wellness centers, rehabilitation clinics, dental practices, and elite sports organizations across Europe — underscoring the broad potential of the technology.

An Opportunity for Visionary Investors

Until now, the project has been funded primarily by Czech investors. H2 Global Group is now opening the door to U.S. and global partners at a critical growth stage, with EU registration underway and FDA approval next on the horizon — unlocking the world’s largest healthcare market.

The global Alzheimer’s therapeutics market is projected to exceed $20 billion by 2030, with dementia-related costs already surpassing $1 trillion annually. Positioned as the only functional hydrogen-based therapy of its kind, H2 Global Group offers investors a rare first-mover advantage in one of the most urgent and lucrative markets of our time.

Source: finance.yahoo.com

H2 Brain®: Innovative Support for Mental Well-being at the Cellular Level

H2 Brain®: Innovative Support for Mental Well-being at the Cellular Level

by | Mar 19, 2025 | Alzheimer, Health

H2 Vibe proudly introduces H2 Brain®, an innovative food supplement developed to support mental wellbeing and cognitive performance – both during the day and at night. This unique two-phase formulation respects the body’s natural circadian rhythm and is carefully tailored to meet the brain’s changing needs throughout the day.

Today’s fast-paced lifestyle, combined with a lack of physical activity and chronic stress, is taking a toll on our mental health. “People today live under immense pressure, which often results in poor sleep quality and a general sense of mental unease,” explains Viktória Procházková, CEO of H2 Global Group. “At the same time, data indicates a growing prevalence of neurological disorders, which motivated us to develop a comprehensive solution aimed at supporting cognitive function and emotional balance.”

For nearly a year, the Czech company H2 Global Group fine-tuned the formula to perfection – resulting in H2 Brain®, a two-phase supplement designed to meet the brain’s essential needs and promote mental clarity and emotional resilience. “Throughout the development of H2 Brain®, we paid close attention to the bioavailability and synergistic interactions of each ingredient to achieve maximum efficacy at the cellular level,” adds PharmDr. Milan Krajíček, Head of Research and Production at H2 Pharm.

Targeted Support – Day and Night

H2 Brain® has been developed as a two-phase system to address the brain’s distinct daytime and nighttime needs. The morning tablet is focused on enhancing concentration and cognitive performance throughout the day. It includes Baikal skullcap extract, astaxanthin, and selenium with sustained release properties. The evening tablet, by contrast, is formulated to encourage mental relaxation and restorative sleep, with ingredients such as taurine, B vitamins, and ginkgo biloba.

H2 Brain® also features the patented HydrogenIQ complex, which naturally supports the production of molecular hydrogen. As the smallest molecule in the universe, molecular hydrogen is currently being explored for its unique ability to cross the blood–brain barrier and reach brain cells. Research suggests it may play a beneficial role in promoting cellular regeneration and protecting neurons against oxidative stress.

For Students, Professionals, Parents and Seniors

H2 Brain® is designed for a wide range of individuals – from students seeking to boost focus during intensive study, to professionals and parents managing high cognitive loads, to older adults looking to support mental clarity and cognitive longevity. “Our aim with H2 Brain® was to create a supplement that actively supports brain function and contributes to long-term mental wellbeing,” concludes Krajíček.

According to the World Health Organization (WHO), approximately 55 million people worldwide are currently living with dementia, with around 10 million new cases diagnosed each year. Alzheimer’s disease accounts for 60–70% of these cases. By 2050, the global number of people affected by dementia is expected to rise to 139 million. This alarming trend highlights the urgent need for proactive measures to support brain health from midlife onwards.

Alzheimer’s Dementia: Genetics play a role!

Alzheimer’s Dementia: Genetics play a role!

by | Mar 4, 2025 | Alzheimer

H2 Global Group Holds International Patent for Alzheimer’s Therapy Using Molecular Hydrogen

Ostrava-based company H2 Global Group has secured an international patent for the treatment and mitigation of Alzheimer’s disease through a groundbreaking approach combining hydrogen inhalation devices, hydrogen-rich water, and targeted nutritional supplements. Now, the company is integrating this innovation into a new model of personalised healthcare—with a focus on prevention.

Scientists warn that the number of Alzheimer’s cases is rising sharply, and individuals with close family members affected by the disease are up to four times more likely to develop it themselves.

A Czech Breakthrough with Global Potential

Alzheimer’s does not only affect the elderly—changes in the brain can begin as early as age 40, eventually leading to symptoms associated with various types of dementia. A ray of hope for millions around the world may, however, be emerging from the Czech Republic.

H2 Global Group’s patent—developed in collaboration with Japanese researchers—includes a unique combination of molecular hydrogen inhalation via custom-designed generators, drinking hydrogen-rich water, and targeted supplementation. The company is now planning to introduce a digital tool that can help identify individuals with a genetic predisposition, enabling early intervention and shifting the paradigm from treatment to prevention. This aligns with H2 Global Group’s long-term focus on the development of bioactive nutrients for targeted health outcomes.

“Regular hydrogen inhalation using our H2 Vibe devices can not only alleviate symptoms in those already affected but may also prevent onset—if started early enough,” Photo credit: H2 Global Group

From Scientific Discovery to Scalable Innovation

H2 Global Group is committed to bridging the gap between research and real-world impact.

“We are applying our patents in several ongoing projects, which are often demanding in terms of time, resources, and logistics,” explains CEO Viktória Procházková. “But our core mission is not just scientific exploration—we aim to bring innovations to market swiftly, creating immediate value for both existing and new investors. We are soon launching a new two-phase brain nutrient designed to protect and regenerate the brain. Our goal is to engage at-risk individuals early and offer them effective strategies for maintaining cognitive health.”

Renowned Japanese scientist Professor Shigeo Ohta, a global authority on molecular hydrogen and long-term research partner of H2 Global Group, adds:

“We’ve identified oxidative stress and mitochondrial dysfunction as key contributors to Alzheimer’s. Hydrogen reduces inflammation, supports cognitive function, and plays a vital role in neuron protection and disease management.”

“Early detection, risk mitigation, and prevention must become part of our daily lives if we want to maintain a high quality of life without cognitive decline,” says Viktória Procházková.

Alzheimer’s: A Gateway to Innovation

Alzheimer’s affects over 55 million people worldwide, including more than 150,000 in the Czech Republic. Without intervention, these figures are expected to double by 2050.

Because brain damage may begin decades before symptoms appear, early prevention is critical. Regular hydrogen supplementation and a personalised health approach could significantly slow—or even prevent—the onset of disease.

A Future-Focused Investment Opportunity

H2 Global Group’s patented hydrogen-based therapy represents not only a breakthrough in healthcare—but also a compelling investment opportunity in the future of medicine.

“Hydrogen therapy is proving to be a revolutionary method in both prevention and treatment. Thanks to our proprietary technologies, we are now bringing these innovations from the lab into everyday medical practice,”
explains Martin Frais, Director of H2 Invest.

Combining cutting-edge science with a clear market strategy, the company is creating opportunities for investors seeking stable, forward-looking returns in the MedTech and HealthTech sectors—fields with rapidly growing importance and strong social impact.

“Hydrogen-based technologies have the potential to fundamentally transform how we approach treatment and regeneration. Demand is rising among physicians, researchers, and patients alike. This is a unique moment to participate in innovations that are redefining modern medicine. H2 Group is building a high-growth sector with global relevance and long-term investment potential,”
concludes Frais.

H2 Global Group
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.